CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 36 enrolled
Drug / intervention
rosiglitazone +1 moredrug
Likely dose
Not stated in record
Key inclusion· 4
  • ✓Age 25-75 years
  • ✓Type 2 diabetes mellitus for ≤10 years duration
  • ✓Pre-screening HbA1c >6.5%
  • ✓Fasting plasma glucose 110-240 mg/dL after 2 weeks of metformin 500 mg twice daily
Key exclusion· 12
  • ✕Thiazolidinedione or sulfonylurea use within previous 30 days (unless washed out)
  • ✕Known contraindications to thiazolidinedione or sulfonylurea
  • ✕Subcutaneous insulin use
  • ✕Elevated liver enzymes (≥2.5× upper limit of reference range)

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00123643
NCT00123643Phase 4Completed
CompareCT.gov

Comparison of Rosiglitazone Versus Glyburide on Vascular Structure and Function in Type 2 Diabetic Patients

St. Paul Heart Clinic·interventional·Posted Jul 25, 2005·Updated Jul 15, 2013

In Brief

A Phase 4 clinical trial evaluating rosiglitazone and glyburide for Type 2 Diabetes Mellitus. Completed, enrolled 36 participants across 1 site.

Detailed Summary

The purpose of this study is to compare the vascular effects of two commonly used diabetes medications, rosiglitazone and glyburide in type 2 diabetic patients.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes Mellitus
CountriesUnited States
CollaboratorsGlaxoSmithKline

Timeline

Phase 4CompletedFinished
2003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJul 25, 2005
Enrollment StartMay 1, 2003
Primary CompletionDec 1, 2005
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 20.9 years ago

Interventions

rosiglitazonedrug

glyburidedrug